Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.46 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126267 | 0.79 | P2RX7 (0.62) | NPC1RAB9ASMN1; SMN2KMT2AP2RX7 | |
| SCHEMBL5122075 | 0.79 | P2RX7 (0.62) | NPC1RAB9ASMN1; SMN2KMT2AP2RX7 | |
| SCHEMBL5128753 | 0.78 | P2RX7 (0.54) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5121876 | 0.78 | MAPT (0.51) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5128732 | 0.76 | HIF1A (0.53) | TAAR1NPC1RAB9ASMN1; SMN2P2RX7 | |
| SCHEMBL28762492 | 0.76 | NPC1 (0.71) | TAAR1ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL3837660 | 0.74 | P2RX7 (0.48) | ALDH1A1LMNASMN1; SMN2KMT2AP2RX7 | |
| SCHEMBL3837822 | 0.74 | P2RX7 (0.67) | NPC1RAB9AKMT2AP2RX7 | |
| Hydrochloric Acid SCHEMBL3836582 | 0.74 | P2RX7 (0.66) | NPC1RAB9AKMT2AP2RX7 | |
| SCHEMBL12571909 | 0.73 | P2RX7 (0.47) | ALDH1A1ADORA1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | claimed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | TAAR1 883/4885ALDH1A1 985/4885ADORA2A 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.